Atle Fund Management AB Buys 10,099 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Posted by Francis Steltz on May 20th, 2026

Atle Fund Management AB increased its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 33.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,432 shares of the company’s stock after acquiring an additional 10,099 shares during the quarter. BeOne Medicines comprises approximately 3.9% of Atle Fund Management AB’s portfolio, making the stock its 7th largest holding. Atle Fund Management AB’s holdings in BeOne Medicines were worth $12,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its stake in BeOne Medicines by 16.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,532 shares of the company’s stock valued at $465,000 after purchasing an additional 213 shares during the period. True Light Capital Pte. Ltd. acquired a new stake in shares of BeOne Medicines in the 4th quarter valued at approximately $1,057,000. ProShare Advisors LLC lifted its holdings in shares of BeOne Medicines by 16.1% in the 4th quarter. ProShare Advisors LLC now owns 1,390 shares of the company’s stock valued at $422,000 after buying an additional 193 shares during the period. Abacus Wealth Partners LLC purchased a new stake in shares of BeOne Medicines in the fourth quarter valued at approximately $201,000. Finally, Crossmark Global Holdings Inc. boosted its stake in shares of BeOne Medicines by 31.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 8,214 shares of the company’s stock valued at $2,495,000 after buying an additional 1,973 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at BeOne Medicines

In other news, SVP Chan Henry Lee sold 341 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 1,005 shares of company stock valued at $308,907 over the last ninety days. Insiders own 6.19% of the company’s stock.

BeOne Medicines Stock Up 1.3%

Shares of NASDAQ ONC opened at $297.01 on Wednesday. The firm’s 50-day moving average is $300.33 and its two-hundred day moving average is $321.48. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market capitalization of $32.59 billion, a PE ratio of 66.45 and a beta of 0.50. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $232.78 and a 12-month high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ONC shares. Guggenheim lifted their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wolfe Research began coverage on shares of BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective on the stock. Truist Financial reissued a “buy” rating and set a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $389.15.

Read Our Latest Report on ONC

BeOne Medicines Profile

(Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.